Compare Delta Air Lines, Inc. (DAL) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Delta Air Lines, Inc. vs BIO-TECHNE Corp — how do they compare? Delta Air Lines, Inc. trades at $85.8 (market cap $56.68B), while BIO-TECHNE Corp trades at $71.23 (market cap $11.12B). The key difference: Delta Air Lines, Inc. is far larger — about 5.1× BIO-TECHNE Corp's market cap, and Delta Air Lines, Inc. pays the higher dividend (0.9%). Which is the better fit depends on your goals.
| DAL | TECH | |
|---|---|---|
Market Cap | $56.68B | $11.12B |
Sector | Industrials | Health |
52-Week High | $93.66 | $71.38 |
52-Week Low | $51.15 | $43.31 |
Enterprise Value | $72.00B | $11.20B |
Dividend Yield | 0.9% | 0.45% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Delta Air Lines, Inc.
Atlanta-based Delta Air Lines is one of the world's largest airlines, with a network of over 300 destinations in more than 50 countries. Delta operates a hub-and-spoke system network, where it gathers and distributes passengers across the globe through key locations such as Atlanta, New York, Salt Lake City, Detroit, Seattle, and Minneapolis-St. Paul. Delta's sale of frequent flier miles, particularly to American Express, is a major driver of the firm's profits.
Read more on DAL →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
